Hikma Pharmaceuticals (LON:HIK) Earns "Buy" Rating from Jefferies Financial Group

Key Points

• Hikma Pharmaceuticals has received a "buy" rating from Jefferies Financial Group, with a target price of GBX 2,600, indicating a potential upside of 48.83% from its previous close.
• The stock opened at GBX 1,747 and has seen a decline of 7.3% recently, reflecting market volatility.
• Company insider Said Darwazah sold 13,863 shares recently, indicating significant insider trading activity.

Hikma Pharmaceuticals (LON:HIK - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at Jefferies Financial Group in a research note issued on Thursday, Marketbeat reports. They presently have a GBX 2,600 ($34.73) target price on the stock. Jefferies Financial Group's price target would indicate a potential upside of 48.83% from the company's previous close.

Hikma Pharmaceuticals Stock Down 7.3%

Shares of HIK opened at GBX 1,747 ($23.34) on Thursday. The company has a 50-day simple moving average of GBX 2,031.24 and a 200-day simple moving average of GBX 2,056.16. The firm has a market capitalization of £4.84 billion, a P/E ratio of 17.14, a P/E/G ratio of 2.38 and a beta of 0.41. The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66. Hikma Pharmaceuticals has a 52 week low of GBX 1,690 ($22.58) and a 52 week high of GBX 2,360 ($31.53).

Insider Transactions at Hikma Pharmaceuticals

In related news, insider Said Darwazah sold 13,863 shares of the stock in a transaction dated Friday, May 30th. The shares were sold at an average price of GBX 2,138 ($28.56), for a total value of £296,390.94 ($395,926.98). 30.54% of the stock is owned by company insiders.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.